Supernus Pharmaceuticals Inc


Supernus Pharmaceuticals Inc (SUPN) Investors Are Scared Off by Elimination of Low SPN-810 Dose; Cantor Makes a Bullish Case

Supernus investors are running for the hills, but analyst sees elimination of 18 mg dose as a good move.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts